Noxopharm Announces AU$2.4M Increase to Its Existing Funding Agreement

Celý článek

Australian clinical-stage drug development company Noxopharm announced that it has managed to secure an increase in funding from two of its existing New York-based institutional investors, Lind Global Macro Fund LP and CST Investment Funds. According to the terms of the new agreement, the company has managed to get AU$2.4 million worth of convertible security …

The post Noxopharm Announces AU$2.4M Increase to Its Existing Funding Agreement appeared first on CryptoNewsZ.